Halozyme Therapeutics Interest Expense 2011-2026 | HALO

Interest expense is the amount of interest a company is obligated to pay to creditors for using debt financing (bank loans, bonds, leasing, etc.) during the reporting period.

Includes:

Interest on bank loans
Interest on corporate bonds
Interest on leases
Interest on credit lines and overdrafts

High interest expenses indicate a high debt burden — the company may be vulnerable to rising rates or declining revenue.

Low interest expenses with high profits are a sign of financial stability.

Annual Interest Expense Halozyme Therapeutics

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
21.5 M	23.8 M	16.3 M	1.05 M	7.53 M	20.4 M	11.6 M	18 M	22 M	20 M	5.2 M	5.58 M	3.27 M	-	-

All numbers in USD currency

Indicator range from annual reports

Maximum	Minimum	Average
23.8 M	1.05 M	13.6 M

Quarterly Interest Expense Halozyme Therapeutics

2025-Q3	2025-Q2	2025-Q1	2024-Q4	2024-Q3	2024-Q2	2024-Q1	2023-Q4	2023-Q3	2023-Q2	2023-Q1	2022-Q4	2022-Q3	2022-Q2	2022-Q1	2021-Q4	2021-Q3	2021-Q2	2021-Q1	2020-Q4	2020-Q3	2020-Q2	2020-Q1	2019-Q4	2019-Q3	2019-Q2	2019-Q1	2018-Q4	2018-Q3	2018-Q2	2018-Q1	2017-Q4	2017-Q3	2017-Q2	2017-Q1	2016-Q4	2016-Q3	2016-Q2	2016-Q1	2015-Q4	2015-Q3	2015-Q2	2015-Q1	2014-Q4	2014-Q3	2014-Q2	2014-Q1	2013-Q4	2013-Q3	2013-Q2	2013-Q1	2012-Q4	2012-Q3	2012-Q2	2012-Q1	2011-Q4	2011-Q3	2011-Q2	2011-Q1
5.33 M	6.89 M	6.82 M	-	6.47 M	5.03 M	4.99 M	-	4.79 M	3.19 M	4.54 M	-	7.51 M	3.1 M	1.76 M	-	1.75 M	1.75 M	1.96 M	-	4.99 M	5 M	5.35 M	-	2.08 M	2.61 M	3.2 M	-	4.29 M	4.77 M	5.23 M	-	5.54 M	5.54 M	5.45 M	-	5.25 M	5.25 M	3.88 M	-	1.3 M	1.3 M	1.3 M	-	1.38 M	1.45 M	1.38 M	-	850 K	849 K	848 K	-	-	-	-	-	12.4 K	20.4 K	23.9 K

All numbers in USD currency

Indicator range from quarterly reporting

Maximum	Minimum	Average
7.51 M	12.4 K	3.45 M

Interest Expense of other stocks in the Biotechnology industry

Issuer	Interest Expense	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	4.66 M	-	2.43 %	$ 254 M	Germany
AbCellera Biologics ABCL	-2.71 M	$ 3.56	2.01 %	$ 1.06 B	Canada
Acorda Therapeutics ACOR	31.5 M	-	-24.86 %	$ 820 K	USA
Advaxis ADXS	28 K	-	-9.65 %	$ 45.9 M	USA
I-Mab IMAB	722 K	-	-	$ 866 M	China
Aeglea BioTherapeutics AGLE	29.5 M	-	-	$ 1.01 B	USA
AgeX Therapeutics AGE	4.9 M	-	-10.17 %	$ 12.2 K	USA
Albireo Pharma ALBO	3.69 M	-	-0.23 %	$ 916 M	USA
Aileron Therapeutics ALRN	685 K	-	10.36 %	$ 9.8 M	USA
Ascendis Pharma A/S ASND	80.6 M	$ 231.03	2.23 %	$ 5 B	Danmark
Alterity Therapeutics Limited ATHE	2.28 K	$ 3.61	0.28 %	$ 8.69 B	Australia
Adverum Biotechnologies ADVM	8.23 M	-	-	$ 86.2 M	USA
Applied Genetic Technologies Corporation AGTC	2.67 M	-	-	$ 26.5 M	USA
Applied Molecular Transport AMTI	-4 K	-	-	$ 10.1 M	USA
Arcturus Therapeutics Holdings ARCT	10.1 M	$ 6.63	-0.75 %	$ 182 M	Israel
Akero Therapeutics AKRO	4.67 M	-	-	$ 3.67 B	USA
Athersys ATHX	103 K	-	3.77 %	$ 22.4 M	USA
Akouos AKUS	-1.72 M	-	0.23 %	$ 488 M	USA
Acer Therapeutics ACER	432 K	-	2.71 %	$ 14 M	USA
ARCA biopharma ABIO	9 K	-	1052.0 %	$ 415 M	USA
Allena Pharmaceuticals ALNA	-38 K	-	3.16 %	$ 1.9 M	USA
AlloVir ALVR	1.19 M	-	4.14 %	$ 49.1 M	USA
Aptinyx APTX	737 K	-	-39.0 %	$ 4.57 M	USA
BioNTech SE BNTX	14.2 M	$ 90.54	-0.71 %	$ 27.2 B	Germany
AVEO Pharmaceuticals AVEO	1.6 M	-	-	$ 521 M	USA
Aytu BioScience AYTU	-512 K	$ 2.64	3.94 %	$ 16.6 M	USA
Avenue Therapeutics ATXI	294 K	-	-52.27 %	$ 4.45 M	USA
BioCardia BCDA	3 K	$ 1.27	0.79 %	$ 26.9 M	USA
Autolus Therapeutics plc AUTL	9.29 M	$ 1.51	4.86 %	$ 385 M	Britain
Athira Pharma ATHA	3.96 M	-	-	$ 269 M	USA
Can-Fite BioPharma Ltd. CANF	227 K	$ 3.58	-0.56 %	$ 7.79 B	Israel
Aravive ARAV	2.84 M	-	-13.39 %	$ 1.45 M	USA
Actinium Pharmaceuticals ATNM	1.09 M	$ 1.11	-	$ 33.4 M	USA